Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 11Myelodysplastic Syndromes 7Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Hodgkin Disease 5Burkitt Lymphoma 5Myeloproliferative Disorders 4Multiple Myeloma 4Lymphoma 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Recurrence 3Primary Myelofibrosis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Congenital Abnormalities 3Blast Crisis 3Thrombocythemia, Essential 2Sezary Syndrome 2Precancerous Conditions 2Polycythemia Vera 2

Interventions

daratumumab 4Lenalidomide 3dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Dexamethasone 2Curcumin 2Calcium Dobesilate 2piperine 1isatuximab 1iberdomide 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Leflunomide 1IPH-2101 1Dietary Fiber 1Diet, Mediterranean 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Peripheral Blood Stem Cell Transplantation × 90 days × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡